Back to results
US 2004/0005671 A1Published application
Immunointeractive molecules
AssigneeAmrad Operations Pty. Ltd.
InventorsAndrew Nash, Giuseppe Maccarone, Pierre David Scotney
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeAmrad Operations Pty. Ltd.
InventorsAndrew Nash, Giuseppe Maccarone, Pierre David Scotney
Estimating the term…
The present invention relates generally to immunointeractive molecules and more particularly antibodies which bind to vascular endothelial growth factor-B (VEGF-B) or its functional or structural equivalent and inhibit the biological activity of VEGF-B. In particular the present invention relates to deimmunized such as humanized or human antibodies that bind to VEGF-B and inhibit the biological activity of VEGF-B. These antibodies have uses in the treatment or prevention of diseases associated with perturbations in normal vasculogenesis or angiogenesis or vascular remodelling. The present invention further contemplates a method of modulating diseases associated with perturbations in normal vasculogenesis or angiogenesis or vascular remodelling by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies which bind to VEGF-B and block the biological activity of VEGF-B. Accordingly, a method of screening for inhibitors of the biological activity of VEGF-B is also provided.
An antibody or antigen-binding fragment thereof which binds to mammalian VEGF-B or an antibody-binding portion thereof, wherein the binding of the antibody to VEGF-B antagonizes binding between VEGF-B and VEGF-R1.
A deimmunized, humanized or human monoclonal antibody or an antigen-binding fragment thereof which binds to human VEGF-B or an antibody-binding portion thereof and which inhibits or otherwise reduces VEGF-B binding to VEGF-R1.
A method for producing an antibody having specificity for human VEGF-B, said method comprising immunizing a non-human animal with a VEGF-B polypeptide, or immunogenic part thereof for a time and under conditions sufficient for antibodies directed against the VEGF-B polypeptide to be generated in said animal and then subjecting said antibody to deimmunized or humanization means.
A method for producing a hybridoma cell line comprising immunizing a non-human animal with human VEGF-B or immunogenic part thereof, harvesting spleen cells from the immunized animal, fusing the harvested spleen cells to a myeloma cell line to generate hybridoma cells and identifying a hybridoma cell line that produces a monoclonal antibody that binds VEGF-B or a fragment thereof.
A method for the treatment or prophylaxis of a condition mediated by VEGF-B, said method comprising administering to a subject an effective amount of a deimmunized, humanized or human antibody specific for VEGF-B for a time and under conditions sufficient to inhibit or otherwise reduce VEGF-B signaling via VEGF-R1.
Use of deimmunized, humanized or human monoclonal antibody specific for human VEGF-B or its equivalent in the manufacture of a medicament in the treatment or prophylaxis of a vascular condition in a subject.
Dependencies are inferred from the claim text.